TransGenic Inc. entered into a joint research agreement with Immuno-Biological Laboratories Co. Ltd. The agreement concludes with the immunological biology laboratory to investigate the toxic ß42 (Aß42) was used as an AD therapeutic agent by using TransGenic's model mouse. TransGenic will evaluate effectiveness and efficacy and jointly study the feasibility of development as a pharmaceutical product and as a drug manufacturer as early as possible.